

Miraculins Issued Chinese Patent on PreVu(R) Skin Cholesterol Technology

The Associated Press

(<http://www.miraculins.com/>)

Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, announces today that it has been issued a patent by the State Intellectual Property Office of the People's Republic of China that covers use of a tape stripping device for skin sampling. The issued patent covers elements of the PreVu@ Non-Invasive Skin Cholesterol Lab Processed (LP) Test, specifically relating to the LP collection device, which is used to collect the skin samples which are then sent to a central lab for processing and measuring the skin cholesterol values.

"We have global plans for our PreVu Skin Cholesterol technology," stated Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "This simple to use laboratory based version of the PreVu technology could prove to be very attractive in certain key emerging markets. Miraculins is very enthusiastic about PreVu's potential risk assessment role in the fight against cardiovascular disease, the world's leading cause of death and disability."

The PreVu LP Test non-invasively measures the amount of cholesterol that has been deposited in skin tissues by painlessly and rapidly collecting skin cells from the palm of the hand using a proprietary

medical adhesive collection device, which would then be sealed and sent to a laboratory for processing. The sample collection process is easily self-performed, takes fifteen seconds to conduct and does not require fasting. The PreVu LP Test is Miraculins' second format of its innovative PreVu Non-Invasive Cholesterol Test technology and is being developed as part of a broader commercialization strategy. In Canada, the final development and commercialization of the LP Test is partnered with Gamma-Dynacare Medical Laboratories, one of Canada's largest and most respected medical laboratories.

Miraculins recently announced the Notice of Allowance for a U.S. patent providing coverage on its PreVu Point of Care (POC) Test format, and the launch of a new English Canadian website for PreVu (www.prevu.com(<http://www.prevu.com>)).

About The PreVu@ Non-Invasive Skin Cholesterol Test

Skin cholesterol is the cholesterol that has been deposited and diffused into tissue, as opposed to freely circulating in the bloodstream, and has been shown in clinical trials to be strongly associated with significant coronary artery disease (CAD) as measured by treadmill stress testing, coronary angiography, coronary calcium, carotid artery thickening and carotid artery plaque. The PreVu POC Test is completely painless, non-invasive, involves no blood draw or needles, requires no overnight fasting and involves no handling of potentially hazardous biomaterials. It has been developed to provide new and additive information about CAD risk that is independent of

traditional risk factors, such as blood cholesterol, to help physicians more effectively assess their patients' risk. The test is conducted on the palm of the hand in less than 5 minutes with results being immediately available.

About Miraculins Inc.

Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is partnered with Alere, Inc. (NYSE: ALR) (formerly known as Inverness Medical Innovations), one of the world's largest diagnostic companies.

For more information on Miraculins please visit www.miraculins.com(<http://www.miraculins.com>).

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking statements"). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may" and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins' early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins' filings with Canadian securities regulatory authorities, as well as Miraculins' ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins' forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

PreVu@ is a registered trademark of Miraculins Inc. All Rights Reserved. 2012.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

Miraculins Issued Chinese Patent on PreVu(R) Skin Cholesterol Technology

Published on Medical Design Technology (<http://www.mdtmag.com>)

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.

Source URL (retrieved on 01/30/2015 - 3:23pm):

http://www.mdtmag.com/news/2012/06/miraculins-issued-chinese-patent-prevur-skin-cholesterol-technology?qt-most_popular=0